SCHEMBL1663953

SCHEMBL1663953

CC(C)c1nc2cc(O)ccc2c(=O)n1-c1cccc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.57
ESR1 P03372 2/20 0.46
ESR2 Q92731 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 5/20 0.43
LMNA P02545 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HTT P42858 1/20 0.43
CNR2 P34972 1/20 0.41
GAA P10253 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HCAR1 Q9BXC0 1/20 0.39
GSR P00390 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
POLB P06746 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1664030 0.85 TRPV1 (0.57) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL1663160 0.84 TRPV1 (0.53) TRPV1ESR1ESR2TDP1HSD17B10
SCHEMBL1664223 0.83 TRPV1 (0.55) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL1665874 0.82 TRPV1 (0.54) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL29656833 0.82 TRPV1 (0.65) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL23273575 0.82 TRPV1 (0.65) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL1663099 0.79 TRPV1 (0.47) TRPV1ESR1ESR2ALDH1A1LMNA
SCHEMBL1663889 0.78 TRPV1 (0.57) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL1663899 0.76 TRPV1 (0.60) TRPV1ESR1ESR2HSD17B10ALDH1A1
SCHEMBL1664439 0.76 TRPV1 (0.74) TRPV1ESR1ESR2HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.